Araber
Hvordan tolker du betydningen av dette?

Bravo har vel uttalt at de ønsker å få frem verdiene før eventuell partner.

Publisert i sommer.

First clinical trials for 212Pb have started
between 2012 and 2014 when 18 patients were
treated with TAT. The commercialization of such
treatment is expected by mid-2020.

Collaborators:
In addition to Orano Med, 9 partners from France,
the USA, Norway and Switzerland are involved in
these promising researches (Roche, Radiomedix,
Morphotek, Nordic Nanovector, US National Cancer
Institute, University of Cincinnati, French National
Institute of Health and Medical Research, University
of Alabama at Birmingham, Carat project).


Funker linkene, eller er opplysningene over for gode ?

To learn more on the research partners:
http://www.oranomed.com/EN/home-109/about-
orano-med.html#tab=tab5

Website:
To learn more on this innovative approach:
https://www.orano.group/en/expertise/nuclear-
medicine-against-cancer

To learn more on Orano Med:
http://www.oranomed.com/


Heidelberg | London | New York, 11 April 2019

Springer Nature and DrugPatentWatch partner to provide patent information for drug database.Newly available patent information supports researchers in their strategic decision-making in drug discovery

A new module focusing on patents has been added to the drug pipeline tool AdisInsight. The module allows users to find out which drugs have been patented and when regulatory protection may expire.
“Drug patent information can help key stakeholders in the drug discovery process understand the impact of patent expiry on the competitive landscape, or their market share. They may also be able to evaluate licensing opportunities and explore what opportunities exist for drugs without patent protection, as well as develop end-of-life strategies for their products,” explained Dr. Yali Friedman, Chief Executive of DrugPatentWatch.
Jeff Southwood, Product Development Director for AdisInsight, said: “One of the major struggles our users face is that they have to rely very heavily on patent attorneys or IP specialists to assess patent protection because of the expertise required to find this information in patent-specific databases and to understand and interpret these complex documents. Our goal in developing AdisInsight Patents is to advance the drug discovery process by making drug-centric patent information accessible to any user by including familiar search terms and at-a-glance summaries.”
DrugPatentWatch, a provider of global business intelligence on biologic and small molecule drug patents, will deliver the patent content to AdisInsight. The new AdisInsight patents module is available for existing AdisInsight customers to purchase as an add-on to their subscription or to new subscribers to the platform.

Hvis ledelsen mener at Nano ikke har noe av interesse å tilby BP så er det vel ingen grunn til å ta en aktiv rolle for å få til en partneravtale. Ville jo vært trist om det er tilfelle.

Focus, jeg tror de fleste har forlatt eller sterkt redusert i NN til fordel for PHO og PCIB.
Resultatet blir at de samme personene kommer tilbake om selskapet melder noe bra eller at 40+ brytes...

Proffene gjør jobben for Bravo, hvilken strategi nettløkene tror det ender på betyr null og nada.


Citigate Life Sciences and Healthcare Team provides a unique offering of corporate and financial PR, investor relations and capital markets advisory services to its clients. Our team has diverse sector experience in journalism, in-house biotech, corporate finance, investment research, fund management, consulting and business development, and are well placed to support your financing or partnering objectives. We have dedicated offices in the key financial markets, including London and New York, and are also part of the Huntsworth global network which enables us to support companies globally throughout their life-cycle from start-up, through to public listing and multinationals. Some of our past and current clients include Abingworth, Actelion, Bonesupport, CBMG, Enterome, Eyevensys, Heptares, Hutchinson Chi-Med, Karolinska Development, Medicxi Ventures, MGB Biopharma, Nordic Nanovector, Novexel (acquired by AstraZeneca), ThromboGenics and Transgene.

Er det virkelig ingen som mener noe om hvilken strategi Nano bør følge?

Jeg kan ikke høre Bravo si "Sign on the line that is dotted"